WAT

Business Profile & Competitive Position

Waters Corporation operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. Its core business is designing, manufacturing, selling and servicing analytical technologies, with instruments such as high-performance and ultra-performance liquid chromatography (LC), mass spectrometry (MS), thermal analysis, rheometry and calorimetry (TA). These systems are often sold as integrated LC-MS platforms with common software, and the company supports them with consumables, software and service plans. Following the February 2026 acquisition of BD’s Biosciences and Diagnostic Solutions businesses, Waters also participates in diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry and multiomics tools.

End-market exposure is concentrated in life-sciences research and quality-control workflows: in 2025, pharmaceutical accounts accounted for 59% of net sales, other industrial accounts for 30%, and academic/government agencies for 11%. No single customer represented more than 2% of net sales. Service revenue is a meaningful recurring contributor, representing more than 35% of Waters’ 2025 sales and more than 25% of TA’s 2025 sales.

The reported margin and return figures do not currently point to a wide visible moat in accounting terms. Net margin is 3.6% and return on equity is 1.9%, both relatively low for a company with a strong installed base and recurring service revenue. Those numbers may reflect the early costs and accounting impacts of integrating a major acquisition, but on a trailing basis they suggest profitability is being compressed rather than expanded by scale.

Financial Posture

Waters’ market capitalization stands at $44.8 billion, and the stock trades at a trailing P/E of 113.4. That valuation is notable relative to the company’s current earnings generation: net margin is 3.6% and ROE is 1.9%. A P/E above 100 implies the market is pricing in meaningful profit recovery or growth from the combined Waters-BD Biosciences/Diagnostics entity, rather than rewarding present profitability.

The stock’s beta is 1.15, indicating slightly higher sensitivity to broad market movements than the average name. The company has not reported current debt or leverage in the provided snapshot, but the most recent 10-K notes the BD Biosciences and Diagnostic Solutions acquisition closed on February 9, 2026 for a total purchase price of $16.8 billion including assumed debt. That transaction was structured as a Reverse Morris Trust, leaving BD shareholders with approximately 39.2% ownership of the combined company.

Strategic Priorities & Outlook

According to the company’s most recent SEC 10-K filing, Waters is focused on integrating the large BD Biosciences and Diagnostic Solutions acquisition. The first priority is reorganizing the combined company into four operating segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences. Management is also evaluating the newly organized business activities to determine operating and reporting segments for future reporting periods.

Product development remains a central priority. Waters intends to continue significant R&D investment to develop new products and enhance existing LC, MS, TA and diagnostics offerings. On the operational side, the company plans to pursue additional outsourcing opportunities while maintaining adequate internal supply chain and manufacturing capabilities. These priorities suggest the near-term emphasis is on integration, segment restructuring and pipeline investment rather than near-term margin expansion.

Macro & Geopolitical Exposure

As a Healthcare / Medical – Diagnostics & Research company, Waters is exposed to several macro and geopolitical factors common to the industry. Regulatory clearance and compliance are critical: diagnostic products require approvals such as FDA clearance, and analytical instruments used in regulated pharmaceutical and food-safety laboratories must meet evolving standards.

The business is sensitive to pharmaceutical R&D budgets, which can tighten when drug developers face pricing pressure, patent cliffs or capital-market weakness. Academic and government funding also matters, since 11% of 2025 sales came from those customers. Tariffs, trade restrictions and supply-chain disruptions can affect instrument and consumable manufacturing, while currency fluctuations can impact reported results for a globally deployed installed base. Public-health priorities, reimbursement policy for diagnostic testing, and healthcare cost-containment measures are additional variables that can shift demand for cancer-screening and infectious-disease testing products over time.

Recent Developments

Recent headlines reflect a company leaning into diagnostics partnerships and AI-enabled laboratory workflows. On October 26, 2026, Seeking Alpha published the First Eagle U.S. Value Fund Q3 2026 Portfolio Review, which included Waters among its holdings and is worth reviewing for institutional perspective. On October 23, 2026, Waters and Labcorp announced plans to expand access to cervical cancer screening with what they described as the most comprehensive FDA-approved HPV testing option beginning in late 2026, according to PR Newswire.

Earlier, on October 20, 2026, Zacks reported that Waters launched AI Link to advance AI-enabled LC-MS workflows. The same day, PR Newswire carried news that Waters and Quest Diagnostics would help close the cervical-cancer screening gap by bringing nationwide access to the most comprehensive FDA-cleared at-home HPV screening option. These announcements suggest the new diagnostics portfolio is being commercialized quickly through national laboratory partnerships.

Earnings Behavior & Post-Earnings Drift

Waters has an unblemished earnings beat record over the last eight reported quarters, beating consensus EPS in all eight and producing an average earnings surprise of 4.7%. The post-earnings price tendency has been positive: the average 5-day price move following earnings across those quarters is +2.67%, classified as an upward drift.

Looking at the four most recent quarters:

• August 4, 2026: EPS of $3.05 vs. $3.01 estimate (1.3% surprise) — the stock rose 0.99% the next day and 4.78% over the following five days.
• May 5, 2026: EPS of $2.70 vs. $2.31 estimate (16.9% surprise) — the stock rose 2.04% the next day and 2.83% over the following five days.
• February 9, 2026: EPS of $4.53 vs. $4.51 estimate (0.4% surprise) — the stock fell 0.34% the next day and 2.04% over the following five days, the exception in the recent set.
• November 4, 2025: EPS of $3.40 vs. $3.21 estimate (5.9% surprise) — the stock rose 1.26% the next day and 5.12% over the following five days.

The next scheduled earnings release is November 3, 2026 before market open, with a consensus EPS estimate of $4.00. As of the current snapshot, the share price is $455.98 and the RSI is 64.0, while the 50-day exponential moving average sits at $425.53. The strong historical beat rate and positive average drift are factual patterns, not a forecast; they simply describe how the stock has responded after prior reports.

For a deeper dive into what institutional analysts and major holders are saying about Waters—including consensus modeling around the BD integration, margin trajectory, and the upcoming November 3, 2026 earnings report—readers should look at the full institutional verdict rather than relying solely on summary data points.